Home > Healthcare > Pharmaceuticals > Disease Specific Drugs > pulmonary arterial hypertension pha market
Get a free sample of Pulmonary Arterial Hypertension Market
Your inquiry has been received. Our team will reach out to you with the required details via email. To ensure that you don't miss their response, kindly remember to check your spam folder as well!
Form submitted successfully!
Error submitting form. Please try again.
Get a free sample of Pulmonary Arterial Hypertension Market
Your inquiry has been received. Our team will reach out to you with the required details via email. To ensure that you don't miss their response, kindly remember to check your spam folder as well!
Form submitted successfully!
Error submitting form. Please try again.
Some of the major companies operating in the market are:
These major participants are adopting strategic formulations such as new product development & commercialization, commercial expansion, distribution agreements for business expansion. Moreover, these leaders are investing heavily in developing products, thereby fuelling the revenue generation.
Endothelin receptor antagonist segment will observe a CAGR of 5.5% through 2027 as the drug is highly recommended to reverse the damage of heart & lungs and slow the progression of PAH.
Pulmonary arterial hypertension market size had surpassed USD 6.6 billion in 2020 and will witness a CAGR of 6% through 2027.
Germany held 10% of the market share in 2020 and will record over USD 194 million by 2027 owing to rising prevalence of PAH in the country.
U.S. dominated North America pulmonary arterial hypertension market and will record a valuation of over USD 6.25 billion by 2027 owing to increasing hospital admissions for PAH and growing supportive government initiatives.
Oral segment had captured a revenue share of over 69% in 2020 owing to higher preference for this route of administration due to the convenience and non-invasiveness.